Quel est le prix pour Biocartis Group N.V. (BCART)

Le prix pour Biocartis Group N.V. (BCART) est $0.343985

Quelle est la capitalisation boursière pour Biocartis Group N.V. (BCART)

La capitalisation boursière pour Biocartis Group N.V. (BCART) est $32.31M

Bénéfices de Biocartis Group N.V. (BCART)

Biocartis Group NV is a molecular diagnostics firm dedicated to improving clinical care. Its innovative diagnostic solutions primarily serve the oncology sector, benefiting patients, medical professionals, insurers, and the broader healthcare ecosystem. The company's cornerstone is its exclusive Idylla molecular diagnostics platform, a sophisticated real-time polymerase chain reaction (PCR) system. This technology delivers crucial molecular data, aiding in the selection of appropriate treatments and the continuous monitoring of patient progress. Biocartis offers a range of diagnostic tests via the Idylla system, including mutation analysis for BRAF, KRAS, MSI, EGFR, and NRAS-BRAF. Additionally, it provides Idylla panels for SARS-CoV-2/Flu/RSV, standalone SARS-CoV-2 tests, and the rapid host-response assessment, SeptiCyte RAPID. For research purposes, the company supplies various mutation assays, such as those for MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R. Biocartis has entered into strategic partnerships to broaden its impact. One such collaboration is with Amgen, focusing on evaluating Idylla RAS testing to enable swift, decentralized diagnostics and enhance the accessibility of RAS biomarker data through the Idylla platform and its associated RAS tests. Another key alliance is with Bristol-Myers Squibb Company, centered on the registration and application of the Idylla MSI test within the field of immuno-oncology treatments. Furthermore, a licensing, development, and commercialization agreement with GeneproDx is in place for the creation of the innovative ThyroidPrint genomic test, to be integrated onto the Idylla platform. Established in 2007, Biocartis maintains its corporate headquarters in Mechelen, Belgium.

Année	Bénéfices	Changez
Pas assez de données pour les dates fournies.

Année

Bénéfices

Changez

Pas assez de données pour les dates fournies.

Entreprise	Bénéfices	Différence de bénéfices	Pays
Thermo Fisher Scientific Inc. TMO.US	$7.61B	-	US
Danaher Corporation DHR.US	$4.76B	-	US
WuXi AppTec Co., Ltd. 603259.SS	-	-	CN
Natera, Inc. NTRA.US	$-252.70M	-	US
IDEXX Laboratories, Inc. IDXX.US	$1.42B	-	US

Entreprise

Bénéfices

Différence de bénéfices

Pays